Clinical trials
Kidney Transplant Recipients clinical trials
Below are recruiting kidney transplant recipients clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07370727Recruiting
Weight training for kidney transplant patients
This trial studies whether a personalized weight training program helps kidney transplant recipients improve their strength and health. It is for people who are at least one year post-transplant and have stable kidney function.
Bogotá, Bogota D.C.Ages 18–50 - NCT07368153RecruitingPhase 2
Preventing EBV infection after kidney transplant
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
Bern, Canton of BernAges 18 years+ - NCT07358195RecruitingEarly Phase 1
Combined stem cell and kidney transplant from a relative
This trial tests a combined transplant of blood-forming stem cells and a kidney from the same family member. It aims to help people with both advanced kidney failure and a blood cancer by potentially reducing the need for lifelong anti-rejection medicines.
Boston, MassachusettsAges 18–70 - NCT07341516Enrolling by invitation
Global study of deceased donor kidney use
This study examines all kidneys donated from deceased donors (brain death or circulatory death) between 2010 and 2025 to understand how they are used for transplantation. It may help improve future transplant practices.
Nashville, TennesseeAges Any age - NCT07305012Recruiting
Healthy lifestyle tool for older liver and kidney transplant recipients
This study tests a new tool designed to help people aged 60 or older who have received a liver or kidney transplant improve their eating and physical activity habits. It aims to see if the tool is easy to use and helpful for maintaining a healthy lifestyle.
Bologna, BOAges 60 years+ - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT07290777RecruitingPhase 2
Study of Vel-101 to prevent kidney transplant rejection
This trial tests a new medicine called VEL-101, which is added to standard anti-rejection drugs, to see if it helps prevent the body from rejecting a new kidney. It is for adults receiving a kidney from a deceased or non-identical living donor.
Dallas, TexasAges 18 years+ - NCT07275632RecruitingPhase 1/Phase 2
Testing vonoprazan to prevent delayed kidney function after transplant
This trial tests whether a medicine called vonoprazan fumarate can help prevent delayed kidney function after a first kidney transplant from a deceased donor. It is for people who are ready to follow standard post-transplant care.
ChongqingAges 18 years+ - NCT07266467RecruitingPhase 4
Preventing CMV After First Kidney Transplant
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Xi'an, ShaanxiAges 18 years+ - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75 - NCT04702022Recruiting
Extra PET scan to check for silent kidney transplant rejection
This study tests whether an additional PET scan can help detect and guide treatment for “subclinical” (silent) rejection in people with kidney transplants. It may help doctors spot problems earlier and manage them more appropriately.
Liège, LiègeAges 18 years+ - NCT07143773RecruitingPhase 4
SGLT2i safety in kidney transplant patients without diabetes
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
OdenseAges 18 years+ - NCT07141043Recruiting
Bone health study after kidney transplant
This study looks at bone and mineral disorders in people on dialysis, after a kidney transplant, or with bone thinning. It aims to understand how these conditions affect bone health.
IașiAges 20–70 - NCT07096453RecruitingPhase 1/Phase 2
CMV prevention in kidney transplant patients switching to belatacept
This trial tests whether an experimental drug (CMVIG) can prevent CMV infection in kidney transplant patients who are switching to or already on belatacept, a newer immunosuppressant. It may help protect those at higher risk for CMV.
Minneapolis, MinnesotaAges 18–70 - NCT07053462RecruitingPhase 1/Phase 2
Gene-edited kidney transplant to lower rejection risk
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Beijing, ChangpingAges 16–85 - NCT05005793RecruitingPhase 4
Alkali treatment to improve kidney graft blood vessel function
This trial tests whether adding an “alkali” treatment (to raise low blood bicarbonate) can improve blood vessel and kidney graft function in people whose kidney transplant is about 1 year old. It may help if you have lower-than-normal bicarbonate levels while on stable transplant and blood pressure medicines.
Aurora, ColoradoAges 18–80 - NCT06140537RecruitingPhase 4
Dapagliflozin for kidney and heart health after transplant
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
Aurora, ColoradoAges 18–80 - NCT07033858Recruiting
Short-term effects of Advograf plus Rapamiune after kidney transplant
This trial tests a combination of two medications (Advograf and Rapamiune) given shortly after kidney transplant to see how well they work and how safe they are. It may help improve long-term transplant health.
TehranAges 18 years+ - NCT07006831Recruiting
Blood study for kidney transplant patients
This study collects blood and leftover donor samples from kidney transplant recipients who need a biopsy. The goal is to improve monitoring after transplant.
San Diego, CaliforniaAges 18 years+ - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06881927RecruitingPhase 4
Reducing anti-rejection meds in ICU for kidney transplant patients
This study tests whether quickly reducing your anti-rejection medicines during a life-threatening ICU stay can help your kidneys recover and improve your overall outcome. It is for kidney transplant recipients with septic shock or severe breathing failure.
StrasbourgAges 18 years+ - NCT06824454RecruitingPhase 2
Testing dipyridamole to prevent low phosphate after kidney transplant
This trial tests if a drug called dipyridamole can prevent low phosphate levels after a kidney transplant. It is for adult kidney transplant patients who can safely take the drug.
Stanford, CaliforniaAges 18 years+ - NCT06825117Enrolling by invitation
Probiotics after kidney transplant
This trial tests whether taking a probiotic supplement helps people recovering from a kidney transplant. If you are between 18 and 75 years old and had a smooth recovery in the first month after surgery, you may be able to join.
UdineAges 18–75 - NCT06798909RecruitingPhase 3
CMV prevention in kidney transplant patients
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
San Francisco, CaliforniaAges 18 years+
Hear when a new Kidney Transplant Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for kidney transplant recipients?
- Yes. Clin2 currently lists 146 recruiting kidney transplant recipients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant recipients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant recipients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.